presentation by Alvaro Goyanes, Co-founder and Director of Development, FabRX
3D printing (3DP) is an increasingly growing manufacturing technology that provides the ability to fabricate structures of precise geometries from a 3D model by deposition of many thin layers. 3DP is nowadays used as a production tool or for rapid prototyping in many areas.
In the pharmaceutical field, the claimed advantages of the in situ fabrication of unit dosage forms with doses and/or drug combinations personalised to the patient may change, in the future, medicines design and manufacture of medicines. It is predicted a change from limited dose range dosage forms manufactured in big industries to tailored-to-patient medicines, to meet the therapeutic needs of each individual patient (precision medicine), prepared in community pharmacies or hospitals.
3DP comprises an array of different additive manufacturing technologies of which some can be adapted to the use in pharmaceutics. The feasibility of using 3DP to fabricate immediate release, control release or enteric tablets with pharmaceutical-grade polymers have been demonstrated and the release profiles obtained can be modified by careful selection of the excipients.
The application of these technologies to the pharmacy will make necessary to evaluate, develop and adapt these novel manufacture technologies to the high quality standards demanded and regulated by the pharmaceutical industry, what will lead to new challenges and opportunities.
What drives you?
Together with the passion for healthcare and technology, I think the most important thing is the believe that we are improving people’s life.
Why should the delegate attend your presentation?
I will show the latest advances from FabRx, the company leading 3D printing of personalized medicines
What emerging technologies/trends do you see as having the greatest potential in the short and long run?
Depending on the application all 3DP can be suitable
What kind of impact do you expect them to have?
They will revolutionize the preparation of personalized medicines in hospitals
What are the barriers that might stand in the way?
The main barrier might be a mental one
The future of medicine is 3D
Alvaro Goyanes is co-founder and Development Director at FabRx, honorary lecturer at University College London – School of Pharmacy (UK) and part-time lecturer at the Faculty of Pharmacy – University of Santiago de Compostela (Spain). Alvaro is one of the first researchers to evaluate the opportunities of 3D printing using new 3D printing technologies to manufacture oral dosage forms and medical devices. Alvaro has published more than 50 articles. He has listed amongst the World’s Most Highly Influential Researchers in 2019 by Web of Science and he is a recognized world expert in 3D printing of medicines with more than 100 communications to international conferences.
FabRx was created by leading academics at University College London (UCL), with a passion for developing better medicines using 3D printing. We believe in a world where medical treatment can be personalised to the individual needs of each patient (in terms of dosage, shape, size and dose combinations) for production on site in pharmacies or clinical trials units. In this way, medicine taking is easier, more effective and associated with better patient outcomes.
Established in 2014, FabRx is a small start-up company with a big vision. Using our patented technologies, we provide a novel and flexible platform for the production of personalised medicines, revolutionising medical treatment for patients around the world. The future of medicine is 3D.
Alvaro is speaker at the 2021 edition of the conference.